semaglutide
The FDA’s new rule will likely raise the cost of semaglutide and tirzepatide for Medicaid programs this fall. In April 2026 the FDA announced it would exclude semaglutide, tirzepatide and liraglutide from the 503B bulk list, a move that could add as much as $48 per Medicaid prescription (FDA
oral semaglutide prescribing
The FDA is removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list, effectively ending large-scale compounding of these GLP-1 weight-loss drugs. The move follows a proposal announced in April 2024 and aims to curb unauthorized use while protecting the integrity of FDA-approved formulations. On April 30, 2024, the agency
503b exclusion semaglutide
3 Surprising Things About Semaglutide's 503B Exclusion The FDA’s proposal to exclude three GLP-1 drugs from the 503B bulks list means clinics can no longer rely on compounding pharmacies for bulk semaglutide, tirzepatide, or liraglutide, forcing them to purchase fully labeled vials. The change aims to curb
503b bulks exclusion
Excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list could cost hospitals as much as $200 million per year in added drug costs. That figure reflects the combined price differential between bulk-compounded GLP-1 products and commercially sourced injectables, a gap that will widen as compounding pharmacies lose access to
ozempic rebound weight
Taking a short break from Ozempic or similar GLP-1 drugs can quickly erase weight-loss gains, often within weeks. Patients who pause therapy lose the metabolic momentum built over months, and the rebound can be sharper than the original weight gain. The following analysis draws on recent clinical observations and FDA
wegovy women's obesity data
To avoid the seven common mistakes in women’s obesity treatment with Wegovy, clinicians should personalize dosing, start therapy early, monitor gastrointestinal tolerance, combine GLP-1 therapy with behavioral counseling, and stay aware of FDA compounding restrictions. Data unveiled this week shows that women on Wegovy® gained 8% of body weight
semaglutide bulk cost
The FDA’s decision to pull semaglutide and tirzepatide from the 503B bulks list will raise bulk purchase costs by roughly 40%, forcing clinics to shift sourcing strategies. This change impacts wholesale pricing, pharmacy workflows, and patient out-of-pocket expenses across the United States. Medical Disclaimer: This article is for informational
fda compounding glp‑1 restriction
Telehealth can still thrive, but it must redesign its supply chain and compliance workflow after the FDA barred bulk compounding of semaglutide, tirzepatide and liraglutide. I explain the new hurdles, practical workarounds, and what clinics can do to keep patients on GLP-1 therapy. Medical Disclaimer: This article is for informational
503b bulk list
The FDA’s move to pull semaglutide, tirzepatide and liraglutide from the 503B bulk list will raise prices for rural pharmacies, shrink drug availability and force clinics to renegotiate compounding contracts. 81% of small-company compounding pharmacies reported a 2% overhead reduction before the proposal, meaning the new direct fees are
fda 503b exemption
Three health plans have already missed up to 30% of projected savings after the FDA’s 503B proposal removed key GLP-1 drugs from bulk compounding. The rule forces insurers to shift from low-cost bulk purchases to higher-price point-to-point contracts, straining budgets and disrupting patient access. Medical Disclaimer: This article is
tirzepatide start guide
Prescription weight-loss drugs can cost up to $1,800 per month, so budgeting is essential for most patients. This high price makes the choice between semaglutide and tirzepatide as much a financial decision as a medical one. Understanding the true cost of therapy helps you avoid unexpected out-of-pocket expenses. Medical
semaglutide
Secret Semaglutide Exclusion Swings Small Pharmacies The FDA’s decision to remove semaglutide and tirzepatide from the 503B bulk list will raise sourcing costs for small compounding pharmacies, potentially limiting patient access to affordable GLP-1 weight-loss therapies. Discover how a single regulatory tweak could trigger a domino effect, driving up